Trial Profile

A First Clinical Trial of Exosomes Derived from Human Mesenchymal Stem Cells to Target Autism

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exosome therapies (Primary)
Indications Autistic disorder
Focus Adverse reactions
Sponsors Stem Cell Medicine

Most Recent Events

24 Apr 2019 New trial record
23 Apr 2019 According to a Stem Cell Medicine media release, the company is preparing for first clinical trial this year, which will target autism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com